AI Foundation Models Are Reshaping Biomedical Research and Drug Discovery
A new Nature Biotechnology review maps how large-scale AI foundation models are transforming biomedicine, from genomics to clinical diagnostics.
Summary
Researchers from Ohio State University and collaborating institutions have published a comprehensive review in Nature Biotechnology tracing the rapid emergence of biomedical foundation models — large AI systems pre-trained on massive biological and clinical datasets. These models, inspired by breakthroughs like GPT and AlphaFold, are being applied across genomics, proteomics, drug discovery, pathology, and clinical decision-making. The review charts how these tools are moving from research curiosities to practical instruments capable of predicting protein structures, interpreting medical imaging, and identifying disease biomarkers. For longevity researchers and clinicians, this shift matters enormously: AI foundation models could accelerate the identification of aging mechanisms, streamline drug repurposing, and enable more personalized medicine. The paper signals that biomedical AI is entering a new era of scale and capability.
Detailed Summary
Artificial intelligence is undergoing a foundational shift, and biomedicine is at the center of it. Large-scale AI models — trained on vast, diverse datasets and capable of generalizing across many tasks — are now being developed specifically for biological and clinical applications. A new review in Nature Biotechnology traces this rise and examines what it means for the future of medicine and health research.
The authors, based at Ohio State University, Houston Methodist Research Institute, and the University of South Florida, systematically map the landscape of biomedical foundation models. These include models trained on genomic sequences, protein structures, electronic health records, medical imaging, and scientific literature. The review covers how these models are built, what data they consume, and where they are being deployed.
Key areas of application include genomics and epigenomics, where foundation models can predict gene expression and regulatory elements; proteomics, where models like ESMFold extend AlphaFold's structural prediction capabilities; pathology and radiology, where vision-language models interpret tissue slides and scans; and drug discovery, where models accelerate molecular design and target identification. The authors also address clinical NLP models that extract insights from patient records at scale.
For longevity science, the implications are significant. Foundation models could dramatically speed up the identification of aging biomarkers, the discovery of geroprotective compounds, and the analysis of multi-omic datasets that characterize biological aging. They may also enable more precise patient stratification in clinical trials targeting age-related diseases.
Caveats remain. Foundation models require enormous computational resources, raise data privacy concerns, and can encode biases present in training data. Regulatory frameworks for clinical deployment are still evolving. Nonetheless, this review signals that biomedical AI has reached an inflection point, and practitioners across research and clinical settings should begin engaging with these tools now.
Key Findings
- Biomedical foundation models now span genomics, proteomics, imaging, EHRs, and drug discovery applications.
- These AI systems generalize across multiple tasks after pre-training on large biological datasets, reducing need for task-specific models.
- Foundation models could accelerate aging biomarker discovery and geroprotective drug identification.
- Clinical deployment faces hurdles including data privacy, computational cost, and evolving regulatory standards.
- The field is at an inflection point, with models moving from research tools to practical clinical instruments.
Methodology
This is a review article published in Nature Biotechnology that systematically traces the development and application of biomedical foundation models across multiple domains. The authors synthesize literature spanning AI architecture, biological data modalities, and clinical use cases. Specific inclusion criteria and search methodology are not detailed in the abstract.
Study Limitations
This summary is based on the abstract only, as the full text is not open access; specific findings, model comparisons, and data sources discussed in the paper cannot be verified. As a review article, the conclusions reflect the authors' synthesis and framing rather than original experimental data. Potential selection bias in which models and studies are highlighted cannot be assessed without full-text access.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.